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Abstract
Background: Data on the efficacy of intercellular adhesion 
molecule-1 antisense oligonucleotide alicaforsen in ulcer-
ative colitis (UC) is inconsistent. Methods: All patients, who 
had received at least one dose of alicaforsen, were analyzed 
retrospectively. Alicaforsen’s efficacy was assessed in pa-
tients treated for left-sided UC and proctitis by comparing 
clinical and (if applicable) endoscopic disease activity be-
fore/after treatment. Results: Twelve patients were treated 
for left-sided UC or proctitis. Eleven patients received a 
6-week course of a once-daily 240 mg alicaforsen enema for-
mulation. In 1 patient, treatment was discontinued, because 
it was found to be inefficient. Disease activity measured by 
the partial Mayo score and 6-point symptom score was sig-
nificantly reduced after treatment (6.0 vs. 2.4, p = 0.011 and 
3.7 vs. 1.4, p = 0.008). Faecal calprotectin showed a trend to-
wards reduction (484.4 vs. 179.5 μg/g, p = 0.063). Clinical im-
provement was achieved in 10 patients (83.3%). In 7 pa-
tients, a relapse occurred (70%). Median duration of clinical 
improvement was 18.0 weeks (range 1–112). Three patients 
showed an ongoing improvement of >9 months. No adverse 
events were reported. Conclusions: A 6-week course of ali-
caforsen seemed to be safe and efficacious in inducing clini-
cal improvement in patients with left-sided UC and proctitis. 
Prolonged clinical improvement was observed in many but 
not all patients. © 2017 S. Karger AG, Basel
Introduction
Gut-selective immunosuppressive agents, such as ve-
dolizumab or mongersen, are very promising given their 
good efficacy, but have lower rates of side-effects com-
pared to anti-tumor necrosis factor (TNF) treatment [1–
3]. Infectious complications of anti-TNF remain a sig-
nificant concern in clinical treatment decision and devel-
opment of highly gut-selective therapies interacting with 
gut inflammation, but preserving systemic immune re-
sponse has become a priority in the field of inflammatory 
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bowel disease (IBD) research [4]. Such therapies take ad-
vantage of the specific molecular interactions in leuko-
cyte trafficking [5]. Leukocyte trafficking is a multistep 
process involving both the immune and the endothelial 
cells, which enables direction of leukocytes to the site of 
inflammation: leukocytes tether, get activated, adhere to 
the endothelium and finally migrate through the endo-
thelial layer. For this sequence, interaction between pro-
teins on the surface of leukocytes and their corresponding 
ligands are crucial: integrins are expressed on immune 
cells and bind to their counterpart molecules of the im-
munoglobulin superfamily on endothelial cells. The latter 
consists of intercellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule or mucosal vascular ad-
dressin cell adhesion molecule. While mucosal vascular 
addressin cell adhesion molecule interacts with α4β7 in-
tegrin, which is therefore causative for the efficacy of ve-
dolizumab, ICAM-1 is a transmembrane glycoprotein ex-
pressed on the surface of intestinal epithelial cells and vas-
cular endothelial cells that binds to β2 integrins and 
therefore promotes firm adhesion of leukocytes to the en-
dothelium [6, 7]. Expression of ICAM-1 is upregulated by 
TNFα, interleukin-1, interferon-γ and/or lipopolysac-
charide [8]. Inflammation triggered by those factors (such 
as in IBD) results in an increased leukocyte adhesion and 
trafficking. Several studies suggest that an increased ex-
pression of ICAM-1 is a part of the pathology of IBD [9–
14], which has led to the idea of blocking the ICAM-1 
pathway in IBD treatment.
Alicaforsen is a human ICAM-1 antisense oligonucle-
otide, which blocks ICAM-1 production by complemen-
tary hybridization to the messenger ribonucleic acid of 
the target gene resulting in hydrolysis of the created de-
oxyribonucleic acid-ribonucleic acid (DNA-RNA) com-
plex by an RNase enzyme [15]. While the systemic ad-
ministration of alicaforsen in Crohn’s disease (CD) was 
not efficacious [16–18] and 2 randomized-controlled tri-
als evaluating the role of topical alicaforsen in ulcerative 
colitis (UC) failed to show short-term efficacy, patients 
treated with the enema formulation seemed to have a 
long-term benefit [19–21]. This has led to the hypothesis 
of a disease-modifying effect. In addition, 2 small, open 
label studies evaluating the role of alicaforsen in chronic 
pouchitis have shown promising results even in difficult-
to-treat cases [22, 23].
Taken together, there might be a role for topical alica-
forsen in the treatment of chronic pouchitis and left-sid-
ed UC. This case series analyzes the efficacy and safety of 
a 6-week course of alicaforsen as enema formulation in 
the treatment of left-sided UC and ulcerative proctitis.
Methods
Subjects
We performed a retrospective analysis on all patients who had 
received at least one dose of alicaforsen at 6 IBD referral centers 
in Switzerland with at least one follow-up visit (University Hospi-
tal Zurich, Triemli Hospital Zurich, Gastrozentrum Hirslanden 
Zurich, Tiefenauspital Bern, Kantonsspital St. Gallen, and the out-
patient clinic MagenDarm AG Basel). Patient information was ex-
tracted from each patient’s chart. Patients were excluded if they 
were under the age of 16. Diagnosis of underlying IBD had to be 
established based on clinical course, endoscopy and histology ac-
cording to current international guidelines. As alicaforsen has 
currently an off-label status in Switzerland, approval from the pa-
tient’s health care insurance for reimbursement and from the 
Swiss Agency for Therapeutic Products (SwissMedic) was needed 
prior to the first administration. The drug was used as retention 
enema, which is based on hydroypropyl-methylcellulose in a vol-
ume of 60 mL (4 mg/mL corresponding to 240 mg) and applied 
nightly for 6 weeks. Formulation was prepared by the manufac-
turer (Atlantic healthcare). For a detailed outcome analysis, only 
patients treated for left-sided UC and/or ulcerative proctitis were 
included. Patients were enrolled in the Swiss IBD Cohort Study, 
which an ethical approval is available for. Written informed con-
sent had been obtained from every single patient. 
Data Collection
The following data was collected from individual patient’s 
charts: patient demographics (sex, age, smoking status), prior 
medical and surgical history, prior therapies and current co-med-
ications, disease characteristics (age at disease onset, disease loca-
tion disease course), laboratory parameters (full blood count, C-
reactive protein, blood sedimentation rate, faecal calprotectin), 
endoscopic findings (if applicable) and symptom severity (stool 
frequency, rectal bleeding). In order to grade clinical disease activ-
ity we used the partial Mayo score and a 6-point symptom score 
adapted from the Mayo score [24], which both had been used in 
UC studies [25]. In addition, disease activity was globally assessed 
by the treating physician based on his interpretation of clinical, 
endoscopic and histological findings ranging from remission to 
mild, moderate, and severe activity. If applicable, total Mayo score 
was calculated. We further collected all data on the use of alica-
forsen including exact indication, dosage, duration and side ef-
fects. In order to evaluate the efficacy of alicaforsen, we used the 
following definitions of clinical improvement in accordance to our 
prior study evaluating alicaforsen in chronic pouchitis [23]:
Presence of all of the following criteria:
– Reduction of stool frequency
–  Reduction of partial Mayo score and/or 6-point symptom score
– Responsible clinician considers disease course as improve-
ment in synopsis of clinical symptoms, quality of life and – if ap-
plicable – endoscopic findings.
The last visit within 3 months before the initiation of alicaforsen 
was taken as pre-treatment evaluation. Endoscopic findings were 
excluded if endoscopy was performed >1 year before baseline assess-
ment. Re-assessment of disease activity had to be done within 
6 months after treatment initiation. Relapse was defined as increas-
ing clinical and/or endoscopic disease activity after a period of clini-
cal improvement. Duration from clinical improvement (at the end 
of treatment) to first relapse was recorded for Kaplan-Meier analysis.
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Statistical Analyses
For all statistical analyses, SPSS version 22.0.0 (2013 SPSS Sci-
ence, Inc., Chicago, IL, USA) was used. Metric data is shown as 
medians with total range. Categorical data is summarized as the 
percentage of the group total. For outcome analysis (before vs. af-
ter), Wilcoxon signed rank test was used for ordinary data and for 
continuous variables as they showed a non-normal distribution. 
For calculation of the clinical improvement-to-relapse-time, a Ka-
plan-Meier analysis was performed. A 2-sided p value of <0.05 was 
regarded as statistically significant.
Results
Overview of Patients Treated with Alicaforsen
We identified 30 patients with at least one-follow-up 
visit, who had received at least one dose of alicaforsen. 
The median age was 37.5 years (17.0–69.5) when treat-
ment with alicaforsen was initiated. Twenty-nine patients 
were affected by UC, while 1 patient had been diagnosed 
with CD. The median age at IBD diagnosis was 24.4 years 
(7.5–59.0). At the time of the initiation of alicaforsen, the 
median duration of IBD was 12.8 years (1.5–43.2). Indica-
tion for alicaforsen treatment was as follows: 12 patients 
were being treated for left-sided UC or proctitis, while 16 
were treated for chronic pouchitis after proctocolectomy, 
1 patient was treated for CD proctitis and 1 patient for 
ischemic pouchitis. Only in 2 patients (1 treated for CD 
proctitis and 1 for left-sided UC colitis), alicaforsen was 
discontinued early after 10 days and 5 weeks respectively. 
In both cases, lack of efficacy was the reason for early dis-
continuation. Twenty-four of the 30 patients showed an 
improvement of the underlying condition based on the 
physician’s global assessment. Nineteen of those patients 
experienced a relapse with a median duration from im-
provement to relapse of 12 weeks (1–112). No adverse 
events were reported. Results of those patients treated for 
chronic refractory pouchitis have been published in a pri-
or case series [23]. Demographic data of all patients are 
depicted in Table 1. Online supplementary Table 1 (for 
all online suppl. material, see www.karger.com/
doi/10.1159/000484979) shows a synopsis of all 30 pa-
tients treated with at least one dose of alicaforsen.
Patients Treated for Left-Sided UC/Proctitis
The 12 patients treated for left-sided UC or proctitis 
had a median age of 36.7 years (range 17.0–69.5). Five 
patients were female (41.7%). The median age at UC di-
agnosis was 25.0 years (7.5–59.0). Median duration of UC 
at initiation of alicaforsen treatment was 11.8 years (1.5–
14.8). Seven of the 12 patients (58.3%) had left-sided UC 
(Montreal Classification E2), while the remaining 5 pa-
tients (41.7%) were affected by ulcerative proctitis (Mon-
treal Classification E1). Table 2 depicts demographic data 
and disease characteristics of those 12 patients treated for 
left-sided UC/proctitis. No history of C. difficile infection 
was reported, while 1 patient previously had had a CMV 
colitis. Four patients were prior smokers. One patient 
with proctitis had previously undergone left-sided hemi-
colectomy due to sigmoid perforation. Eleven of the 12 
patients (91.7%) received a full 6-week course of 240 mg 
alicaforsen once daily as enema formulation, while in 1 
patient, alicaforsen was discontinued early after 5 weeks 
due to lack of efficacy. No adverse events were reported. 
Indications for the use of alicaforsen were as follows: to 
defer systemic treatment despite a severe disease course 
(6/12, 50.0%), malcompliance with oral medications 
(1/12, 8.3%), severe course despite prior topical steroids 
Table 1. Demographic data of all patients
All patients (n = 30)
Age, years, median (range) 37.5 (17.0–69.5)
Gender, male/female, n (%) 17/13 (56.7/43.3)
Indication, n (%)
Chronic pouchitis
Left-sided UC/proctitis
Ischaemic pouchitis
Fistulizing CD
16 (53.3)
12 (40.0)
1 (3.3)
1 (3.3)
Table 2. Demographic data and disease activity of those patients 
treated for left-sided UC/proctitis
All patients with 
left-sided UC/
proctitis (n = 12)
Age, years, median (range) 36.7 (17.0–69.5)
Gender, male/female, n (%) 7/5 (58.3/41.7)
Age at UC diagnosis, years, median (range) 25.0 (7.5–59.0)
Duration of UC at alicaforsen treatment, 
years, median (range) 11.8 (1.5–14.8)
Number of daily stools, median (range) 7.0 (1.0–10.0)
Mayo score, median (range) 9.0 (4.0–11.0)
Partial Mayo score, median (range) 7.0 (1.0–8.0)
6-Point symptom score, median (range) 4.5 (0.0–5.0)
Global assessment, n (%)
Mild
Moderate
Severe
2 (16.7)
4 (33.3)
6 (50.0)
Faecal calprotectin, μg/g, median (range) 401.0 (116.0–1,110.0)
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and immunosuppressive agents (1/12, 8.3%), pregnancy 
with aminosalicylate (5-ASA) intolerance (1/12, 8.3%), 
and left sided UC before switch of anti-TNF (2/12, 16.7%). 
Physician’s global assessment revealed a moderate-to-se-
vere disease activity in 10 out of 12 patients (83.3%). Only 
2 patients were assessed to have mild disease. No patient 
was in remission. At baseline, median Mayo score was 9.0 
(4.0–11.0), partial Mayo score was 7.0 (1.0–8.0) and 
6-point symptom score was 4.5 (0.0–5.0). Patients report-
ed a median of 7 stools per day (1–10). For a comprehen-
sive synopsis on each individual patient, we refer to the 
online supplementary Tables 2 and 3.
Overall Study Outcome
Median follow-up (time from treatment initiation to 
first follow-up visit) was 3.0 months (1.6–5.5 months). Six 
of the 12 patients were treated with alicaforsen alone, while 
the remaining 6 patients received concomitant therapy: 1 
patient was treated with overlapping prednisone, which 
was tapered within the first 2 weeks, 1 patient was treated 
with overlapping prednisone for 2 weeks and ongoing ther-
apy with azathioprine and 5-ASA, 1 patient was concomi-
tantly treated with ongoing topical budesonide and 5-ASA, 
1 patient continued with oral and topical 5-ASA, 1 patient 
continued with oral 5-ASA, azathioprine and certolizumab 
pegol, and 1 patient continued with infliximab. Clinical dis-
ease activity was significantly reduced at the first follow-up 
visit. Mean partial Mayo score and the 6-point symptom 
score (adapted from Mayo score) showed a decrease from 
6.0 to 2.4 and from 3.7 to 1.4 respectively (p = 0.011 and p = 
0.008). Total Mayo score and stool frequency both showed 
a considerable decrease from 8.6 to 5.3 and from 6.2 to 4.0; 
however differences were not statistically significant (p = 
0.092 and p = 0.074). In 5 patients, no follow-up endoscopy 
was performed: in 2 patients because of a decrease of symp-
tom severity and normalization of faecal calprotectin (from 
1,110 to 16 and 743 to 16 μg/g, respectively), in 1 patient 
because of the complete absence of clinical symptoms (par-
tial Mayo score 0), in 1 patient due to the very short period 
of clinical improvement (1 week) and in 1 patient due to 
loss of follow-up after clinical re-assessment showing clin-
ical improvement (partial Mayo score pre 4 vs. post 2). Fae-
cal calprotectin as a marker of intestinal disease activity was 
considerably reduced after alicaforsen treatment (mean 
484.4 vs. 179.5 μg/g); however, the difference did not reach 
statistical significance (p = 0.063), as a complete set (both 
pre- and post-treatment) was available only for 7 of the 12 
patients. For subgroup analysis, we excluded patients with 
mild disease at treatment initiation – as those are less likely 
to benefit from alicaforsen. This moderate-severe disease 
subgroup (n = 10) showed the following pre vs. post-treat-
ment changes: Mayo score 9.5 vs. 6.8 (p = 0.197), partial 
Mayo score 6.8 vs. 2.9 (p = 0.020), 6-point symptom score 
4.2 vs. 1.7 (p = 0.013), stool frequency 7.15 vs. 4.6 stools/day 
(p = 0.110) and faecal calprotectin 554.8 μg/g vs. 208.0 (p = 
0.075).
Clinical improvement was achieved in 10 out of the 12 
patients (83.3%). Median duration of clinical improve-
ment (at the end of treatment) was 18.0 weeks (1.0–112.0). 
In 7 of the 10 patients with clinical improvement, a re-
lapse was observed (70%). Median time from improve-
ment (at the end of treatment) to relapse was 6 weeks 
(1.0–112.0). Three patients showed a sustained clinical 
improvement; in those patients, the duration of clinical 
improvement was 36, 69, and 73 weeks respectively 
(Fig. 1a–d, 2).
Discussion
This retrospective case series analyzes the efficacy and 
safety of alicaforsen as enema formulation in the treat-
ment of left-sided UC and ulcerative proctitis in 12 pa-
tients in Switzerland. After a median of 3 months, pa-
tients treated with a 6-week course of alicaforsen showed 
a significant reduction in clinical disease activity (as as-
sessed by partial Mayo score and 6-point symptom score). 
We found that 10 out of 12 patients showed a clinical im-
provement on being given alicaforsen; however, in 7 of 
these patients (70%), a relapse occurred. Median duration 
of clinical improvement was 18.0 weeks. In 3 patients 
with a sustained response, the duration of clinical im-
provement was more than 9 months. 
Data on the potential role of alicaforsen in IBD treat-
ment is inconsistent. In CD, randomized-controlled trials 
with intravenous/subcutaneous drug formulation failed to 
show short-term efficacy of alicaforsen (at weeks 12 and 14, 
respectively), although post-hoc analysis suggested higher 
response rates with higher drug concentrations [16–18, 
26]. In left-sided UC, in a small open label study, Miner at 
al. [27] could demonstrate that alicaforsen enema provides 
local treatment without meaningful systemic exposure; at 
week 6, disease activity index was reduced by 46% with 12 
out of 15 patients having achieved clinical improvement. 
Two larger randomized, controlled trials by van Deventer 
et al. [19] failed to show (short-term) efficacy of the enema 
formulation: disease activity at week 6 was not significant-
ly reduced compared to placebo and mesalazine respec-
tively [20]. Nonetheless, a prolonged clinical response was 
observed in both trials with a significant reduction in dis-
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ease activity at weeks 18 and 30 compared to placebo (51 
vs. 18% and 50 vs. 11%) and a significant longer duration 
of response compared to mesalazine (146 vs. 54 days). In a 
smaller randomized controlled trial, van Deventer et al. 
[28] showed both a short-term and long-term benefit from 
alicaforsen enema treatment: disease activity was reduced 
by 78% at day 29 and by 68% at 3 month compared to a 
placebo response of 28 and 11.5% respectively. Given the 
fact that the half-life period of alicaforsen is only 24 h, these 
findings have led to the concept of a disease-modifying ef-
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Fig. 1. a–d Clinical disease activity (partial Mayo score [a], 6-point symptom scale [b], Mayo score [c] and faecal calprotectin [d]) at 
baseline versus at first follow-up visit after treatment. 
Fig. 2. Kaplan-Meier analysis of duration 
of clinical improvement.
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fect. A durable effect may be achieved by modification of 
immunological factors that permit continuous colonic 
mucosal inflammation in UC [20].
Our results with a clear and fast reduction of clinical 
disease activity (Mayo score –27%, partial Mayo score 
–60%, and 6-point symptom score –62%) are consistent 
with those of the open label study by Miner et al. [27] and 
the small randomized-controlled trial by van Deventer 
[28]. The clinical improvement rate of 83.3% (10 out of 12) 
is comparable to that of Miner et al. [27] (clinical improve-
ment in 12/15 patients [80%]). These findings highlight 
the potential short-term benefit from a single 6-week 
course of alicaforsen. However, 7 of the 10 patients with 
initial clinical improvement had a clinical relapse. The 
median duration of clinical improvement of 18.0 weeks 
(corresponding to 126 days) is nearly as high as indicated 
by Miner et al. [20] (146 days). Four patients had a clinical 
improvement of more than 9 months, 3 of them without 
any further IBD treatment, the remaining patient with on-
going topical and oral 5-ASA only. Four patients had a 
clinical improvement of less than or equal to 8 weeks. It 
remains to be determined, who among the patients show 
a prolonged response after a single 6-week course of alica-
forsen and who do not. Repeated treatment courses and/
or maintenance therapy may lead to longer response rates 
as it has been reported in the case series regarding alica-
forsen in the treatment of chronic pouchitis [23]. So far, 
none of our patients had received a second trial due to 
alicaforsen’s status as unlicensed medicine and the diffi-
culty of reimbursement by the Swiss health insurances.
No serious adverse events were reported underlying 
the safety of the topical applied drug. In addition, topical 
delivery was well tolerated and none of the patients 
showed malcompliance. This is especially noteworthy, as 
patients and physicians appear to be somewhat reluctant 
to administer topical treatment options in UC in real-life 
[29].
A limitation of our case series certainly is its retrospec-
tive nature and subsequently the lack of controls and 
blinding. Six patients (50%) received concomitant treat-
ment. However, 4 of the 6 patients only continued the 
medications, which they had been on for a long time. In 2 
patients, oral prednisone was tapered. The tapering of the 
steroids was well tolerated under alicaforsen treatment. 
The 2 patients with prior and ongoing anti-TNF exposure 
did show the worst outcome (1 patient with no improve-
ment, 1 patient with a relapse after 1 week). The concern 
that anti-TNF co-medication may have affected the study 
outcome positively seems to be negligible. In contrast, fail-
ure to respond to anti-TNF may be a negative predictor 
for treatment success with alicaforsen. The presented re-
sults are based on the partial Mayo score and the 6-point 
symptom score (adapted from the Mayo score). Full Mayo 
score was applied only in 7 of the 12 patients due to the 
lack of follow-up endoscopies. However, both the partial 
score and the symptom score have been previously vali-
dated for UC [25]. The study population was limited due 
to the drug’s status as unlicensed medicine and difficulty 
in reimbursement of the study drug from health care in-
surances. However, the study sample was nearly equal to 
that of the open label study by Miner et al. [27].
In conclusion, a 6-week course of alicaforsen was safe 
and efficacious in inducing clinical improvement in left-
sided UC and proctitis, and is – at least in some patients – 
sufficient for maintaining clinical improvement. Further 
studies with more patients are needed to answer the fol-
lowing questions: Who among patients may benefit from 
a single 6-week course? Who may need repeated treat-
ment courses?
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